You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
明德生物(002932.SZ):2020年度淨利預增959.58%-1104.07%
格隆匯 01-12 16:44

格隆匯1月12日丨明德生物(002932.SZ)披露2020年度業績預吿,預計2020年度歸屬於上市公司股東的淨利潤4.4億元-5億元,同比增長959.58%-1104.07%;歸屬於上市股東的扣除非經常性損益的淨利潤4.32億元-4.92億元,同比增長1345.69%-1546.51%。本期業績預吿的歸母淨利潤在扣除2020年度股權激勵支付成本2981.52萬元後較2019年同期仍大幅增加,主要原因包括:

1、新冠疫情爆發前期,公司依託多年研發積累的分子快速診斷技術基礎,快速研發推出的新型冠狀病毒核酸檢測試劑盒具備預混式操作簡單、反應快速以及高靈敏度的優勢,3月中旬通過國家藥監局應急審批後迅速得到醫療機構用户的認可,併入圍多個省市的集中採購和掛網採購,報吿期內新增約1500家醫療機構分子用户,極大提升了新冠核酸試劑的品牌效應,報吿期內新冠核酸試劑的收入佔比約為總營收的60%。同時,PCR實驗室建設項目以及其他核酸檢測相關產品的銷售也大幅增加;

2、公司全資子公司武漢明志醫學檢驗實驗室有限公司為武漢市定點的核酸檢測機構之一,在此次疫情中承擔了武漢市疫情檢測任務的重要工作,相關的檢測服務收入也大幅增加,約為總營收的8%;

3、公司免疫層析產品2020年下半年度恢復了正常銷售水平,新產品線中全血化學發光產品、血氣產品以及急危重症信息化產品均啟動了市場銷售並取得顯著進展。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account